New report analyses Mainland China's transformation into a
global biopharma powerhouse, with key insights for international
stakeholders
LONDON, Nov. 18,
2024 /PRNewswire/ -- Clarivate
Plc (NYSE:CLVT) a leading global provider of transformative
intelligence, in partnership with Healthcare Executive,
published by the China Pharmaceutical Enterprises Association,
today announced the release of a new report, A Decade of
Innovation, A Decade to Come.
Over the past decade, Mainland China's biopharmaceutical sector
has rapidly advanced to become a global leader in innovation,
ranking among the top three for initial drug launches. Driven by
reforms, increased investment, and progressive policies, the
industry has reduced approval timelines, raised regulatory
standards, and improved patient access to advanced therapies.
Insights from the Institute for Scientific Information™ show that
China's Gross Expenditure on
Research and Development has grown 3.5 times over the past decade,
outpacing growth rates in the UK and the U.S.1 These
developments, combined with an evolving healthcare reimbursement
system, have enabled both domestic and multinational companies to
bring new therapies to market, benefiting millions of patients.
Henry Levy, President, Life
Sciences & Healthcare, Clarivate, said: "Mainland
China's ascent in the biopharma sector reflects the power of
sustained investment and strategic reform. This report not only
highlights the impressive achievements of the past decade but also
underlines the far-reaching potential for Chinese biopharma
companies to drive global medical innovation and enhance patient
outcomes worldwide."
Tan Yong, Vice
President of China Pharmaceutical Enterprises Association and
Publisher of Healthcare Executive, noted: "The
pharmaceutical industry is poised for significant and
transformative changes in the upcoming decade, driven by heightened
competition. Rapid innovation and intense competition have reshaped
market dynamics, leading to more focused and sustainable growth.
The report offers the industry a glimpse of how Chinese
pharmaceutical companies can prioritize innovation and
international expansion in the next decade."
Alice Zeng, Senior Solution
Consultant, Life Sciences & Healthcare, Clarivate, added:
"This report is an invaluable resource for global industry
stakeholders. For pharma companies worldwide, it provides a timely
understanding of Mainland China's biopharma landscape, covering the
opportunities for international collaboration and the potential for
accelerated market entry."
The report highlights Mainland China's regulatory advancements,
rapid drug launch growth, and expanding domestic R&D role. Key
updates include the National Reimbursement Drug List (NRDL), where
systematic price negotiations have cut costs by 50-60%, improving
access to innovative drugs. Additionally, Mainland China's share of
global licensing and service deals has grown from 6.5% to nearly 9%
since 2015, and the country now leads in publishing research and
filing patents in key life sciences, underscoring its rising
influence on the global industry.
Key insights in A Decade of Innovation, A Decade to
Come, include:
- Impactful policy reforms: How regulatory initiatives
such as the Marketing Authorization Holder (MAH) system and
priority review programs have streamlined approvals and bolstered
R&D.
- Healthcare accessibility and innovation: An examination
of Mainland China's healthcare reforms, including the expansion of
the NRDL and commercial health insurance, increasing access to
cutting-edge therapies.
- Investment and R&D growth: Analysis of Mainland
China's record-breaking R&D investment, driving advancements in
oncology, anti-infectives, and emerging therapeutic areas.
- Global Integration and market opportunities: Insights
into the rise of Mainland China's biopharma sector as a global
player, including the increase in multinational collaborations and
first-to-market launches.
With Mainland China's share of first-time global drug launches
growing, and as new therapeutic areas advance, A Decade of
Innovation, A Decade to Come provides timely, in-depth insights
for international investors, multinational pharmaceutical
companies, and healthcare stakeholders who seek to understand
Mainland China's role in shaping the future of the biopharma
landscape.
The A Decade of Innovation, A Decade to Come report draws
on comprehensive data and tools trusted by the global life sciences
community, including Cortellis Competitive Intelligence, Cortellis
Regulatory Intelligence™, Disease Landscape & Forecast,
Cortellis Deals Intelligence, Cortellis Clinical Trials
Intelligence™, Cortellis Product Intelligence™, Real World Data and
Analytics, Access and reimbursement payer studies, BioWorld™, Web
of Science™ and Derwent Innovation™ among others. Compiled by
Clarivate analysts using data gathered prior to August 31, 2024, this report reflects Clarivate's
commitment to supporting drug, device, and medical technology
lifecycles. By combining patient journey data, therapeutic
insights, and AI-driven analytics, Clarivate enables evidence-based
decisions that advance human health.
To learn more about the Clarivate report, A Decade of
Innovation, A Decade to Come, visit here.
About Healthcare Executive
With media as the outpost, conference as the platform, live video
broadcasting as the tool, and expert pharmaceutical industry
observers and recorders as the living force, Healthcare Executive
(E药经理人) brings the top consensus of entrepreneurs, scientists, and
investors in the pharmaceutical industry together on the one hand,
and on the other hand gathers multi-dimensional and multi-level
resources from the whole industry chain. We are dedicated to
providing in-depth professional communication opportunities and
influential solutions for the whole industry chain in their whole
life cycle. In this regard, we make connections with client
requirements upstream and downstream and make preparations for the
overseas strategy in their international programs.
About Clarivate
Clarivate™ is a leading global provider of transformative
intelligence. We offer enriched data, insights & analytics,
workflow solutions and expert services in the areas of Academia
& Government, Intellectual Property and Life Sciences &
Healthcare. For more information, please
visit www.clarivate.com
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences &
Healthcare
Clarivate
newsroom@clarivate.com
1 Source: Global Research Report: China's research landscape, ISI, Clarivate
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307317.html
SOURCE Clarivate Plc